SELLAS Life Sciences Shares Are Trading Higher After the Company Was Granted FDA Rare Pediatric Disease Designation for Its SLS009 CDK9 Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia, Making It Eligible for a Priority Review...
SELLAS Life Sciences Shares Are Trading Higher After the Company Was Granted FDA Rare Pediatric Disease Designation for Its SLS009 CDK9 Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia, Making It Eligible for a Priority Review...
sellas life sciences股票上漲，在其SLS009 CDK9抑制劑獲得FDA罕見兒童疾病認定治療小兒急性淋巴細胞白血病，使其有資格進行優先審查。
SELLAS Life Sciences Shares Are Trading Higher After the Company Was Granted FDA Rare Pediatric Disease Designation for Its SLS009 CDK9 Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia, Making It Eligible for a Priority Review Voucher Worth Over $100 Million Upon Approval.
sellas life sciences股票價格上漲，因該公司的SLS009 CDK9抑制劑獲得FDA兒科罕見病認定，用於治療兒童急性淋巴細胞白血病，使其符合獲得一張價值超過1億美元優先審評憑證的資格。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。